BioWorld - Monday, March 9, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector

BioWorld Science
BioWorld Science RSS Feed RSS

Parkinson's disease illustration showing neurons containing alpha-synuclein
Neurology/Psychiatric

University of Oxford and Selvita collaborate on compounds that promote α-synuclein aggregate clearance for Parkinson’s

June 6, 2023
The University of Oxford and Selvita SA have established an integrated drug discovery collaboration in the area of Parkinson’s disease. Based on evidence implicating α-synuclein aggregates as the cause of Parkinson’s, the approach looks at the inability of cells to efficiently clear these aggregates, which may lead to the death of neurons and the emergence of characteristic symptoms of the disease. Promoting the ability of nerve cells to rid themselves of these aggregates therefore offers a possible therapeutic strategy for Parkinson’s disease.
Read More
Drug R&D concept image.
Gastrointestinal

Liminal Biosciences announces preclinical pipeline progress

June 6, 2023
Liminal Biosciences Inc. has nominated a lead preclinical candidate, LMNL-6326, from its oxoeicosanoid receptor 1 (OXER1) antagonist program, targeting the treatment of eosinophil-driven diseases such as eosinophilic asthma and atopic dermatitis.
Read More
Neurology/Psychiatric

Psychedelic drugs activate an antidepressant pathway without hallucinogenic effects

June 6, 2023
By Mar de Miguel
Psychedelic drugs could have two distinct overlapping effects based on their affinity for two receptors involved in neuronal plasticity. Scientists at the University of Helsinki have observed that lysergic acid diethylamide (LSD) and psilocin (a drug isolated from the mushroom Psilocybe mexicana) have an antidepressant effect that is independent of their hallucinogenic outcome. These two different pathways are established through their binding to the tyrosine kinase receptor (TrkB), which has an antidepressant nature, or to the serotonin receptor, with a hallucinogenic activity.
Read More
Artificial intelligence and digital health icons
Drug Design, Drug Delivery & Technologies

ASCO 2023: AI has little fad to it and a personalized future

June 5, 2023
By Lee Landenberger
Despite the title of the Sunday, June 4 lead-off presentation at the American Society of Clinical Oncology (ASCO) meeting in Chicago, there was little room left for doubt about the increasingly important place of artificial intelligence (AI) in drug development. The program, Artificial Intelligence for Drug Development: Fad or Future, ultimately pointed to a positive future, with the only faddish part being discarded approaches that no longer work.
Read More